Alzheimer’s disease, astrocytes and kynurenines

Current Alzheimer Research

Volumn 12, Issue 5, 2015, Pages 462-480

  Dézsi, Lívia ^a   Tuka, Bernadett ^a   Martos, Diána ^a   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Alzheimer s disease; Amyloid; Astrocytes; Excitotoxicity; Glutamate; Kynurenines

Indexed keywords

ALPHA AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; EXCITOTOXIN; KYNURENIC ACID; KYNURENINE; MEMANTINE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; TAU PROTEIN; UNCLASSIFIED DRUG; ZONISAMIDE; GLUTAMIC ACID;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN BLOOD FLOW; EXCITOTOXICITY; GLIA CELL; GLUTAMATERGIC SYNAPSE; GLYCOLYSIS; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; NERVE CELL NETWORK; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; BRAIN; GLUTAMIC ACID; HUMANS; KYNURENINE;

EID: 84930885035     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501205150526114000     Document Type: Article

References (239)

1. International WHOaAsD, Ed. Dementia: a public health priority. Geneva: WHO Press (2012).
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population - Prevalence estimates using the 2000 census. Arch Neurol-Chicago 60(8): 1119-22 (2003).
3. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 18(6): 306-13 (2003).
4. Batsch NL, MS, Ed. World Alzheimer Report 2012: Overcoming the stigma of dementia. London: Alzheimer's Disease International (2012).
5. Honig LS, Mayeux R. Natural history of Alzheimer's disease. Aging (Milano) 13(3): 171-82 (2001).
6. Zolezzi JM, Bastias-Candia S, Santos MJ, Inestrosa NC. Alzheimer's disease: relevant molecular and physiopathological events affecting amyloid-beta brain balance and the putative role of PPARs. Front Aging Neurosci 6: 176 (2014).
7. Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med 77(1): 32-42 (2010).
8. Guerreiro R, Hardy J. Genetics of Alzheimer's disease. Neurotherapeutics 11(4): 732-7 (2014).
9. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 362(4): 329-44 (2010).
10. Godoy JA, Zolezzi JM, Braidy N, Inestrosa NC. Role of sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol Neurobiol 50(3): 744-56 (2014).
11. Sudhof TC. Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 80(3): 675-90 (2013).
12. Oliva CA, Vargas JY, Inestrosa NC. Wnt signaling: role in LTP, neural networks and memory. Ageing Res Rev 12(3): 786-800 (2013).
13. Shaerzadeh F, Motamedi F, Minai-Tehrani D, Khodagholi F. Monitoring of neuronal loss in the hippocampus of Abeta-injected rat: autophagy, mitophagy, and mitochondrial biogenesis stand against apoptosis. Neuromol Med 16(1): 175-90 (2014).
14. Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 132(Pt 8): 2048-57 (2009).
15. Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev 15: 6-15 (2014).
16. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 148(6): 1204-22 (2012).
17. Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging 34(4): 1051-9 (2013).
18. Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev 35(6): 1397-409 (2011).
19. Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A. Amyloid beta, glutamate, excitotoxicity in Alzheimer's disease: Are we on the right track? CNS Neurosci Ther 19(8): 549-55 (2013).
20. Jurgensen S, Ferreira ST. Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J Mol Neurosci 40(1-2): 221-9 (2010).
21. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29(4): 918-29 (2009).
22. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 192(1): 215-25 (2005).
23. Avila-Munoz E, Arias C. When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer's disease. Ageing Res Rev 18C: 29-40 (2014).
24. Comim CM, Reis PA, Frutuoso VS, Fries GR, Fraga DB, Kapczinski F, et al. Effects of experimental cerebral malaria in memory, brain-derived neurotrophic factor and acetylcholinesterase activity [correction for acitivity] in the hippocampus of survivor mice. Neurosci Lett 523(2): 104-7 (2012).
25. Nelson PT, Kryscio RJ, Abner EL, Schmitt FA, Jicha GA, Mendiondo MS, et al. Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB. J Alzheimers Dis 16(1): 29-34 (2009).
26. Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6(1): 4- 14 (2009).
27. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6(7): e21954 (2011).
28. Bailey JA, Lahiri DK. A novel effect of rivastigmine on presynaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112(4): 843-53 (2010).
29. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9): 698-712 (2011).
30. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 13(3): 319-29 (2014).
31. Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis--lessons from amyloid precursor protein processing. J Neurochem 117(5): 779-96 (2011).
32. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain 4: 3 (2011).
33. Cabezas IL, Batista AH, Rol GP. The role of glial cells in Alzheimer disease: potential therapeutic implications. Neurologia 29(5): 305-09 (2014).
34. Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, et al. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 287(53): 44593-601 (2012).
35. Li S, Shankar GM, Selkoe DJ. How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? Front Cell Neurosci 4: 5 (2010).
36. Dinamarca MC, Rios JA, Inestrosa NC. Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease. Front Physiol 3: 464 (2012).
37. Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Csh Perspect Med 2(7): (2012).
38. Borlikova GG, Trejo M, Mably AJ, McDonald JM, Sala Frigerio C, Regan CM, et al. Alzheimer brain-derived amyloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging 34(5): 1315-27 (2013).
39. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136(Pt 5): 1383-98 (2013).
40. Popa-Wagner A, Buga AM, Popescu B, Muresanu D. Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm (2013) [Epub ahead of Print].
41. Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda- Hernandez MA, Mena-Lopez R. Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 112(6): 1353-67 (2010).
42. Jia QT, Deng YL, Qing H. Potential therapeutic strategies for Alzheimer's disease targeting or beyond. beta-amyloid: insights from clinical trials. Biomed Res Int 8: 37157 (2014).
43. Zhou W, Cai F, Li Y, Yang GS, O'Connor KD, Holt RA, et al. BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease. J Mol Neurosci 42(1): 127-33 (2010).
44. Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, et al. Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. Neurobiol Aging 35(6): 1513 e1-5 (2014).
45. Natunen T, Parrado AR, Helisalmi S, Pursiheimo JP, Sarajarvi T, Makinen P, et al. Elucidation of the BACE1 regulating factor GGA3 in Alzheimer's disease. J Alzheimers Dis 37(1): 217-32 (2013).
46. Larner AJ. Presenilin-1 mutations in Alzheimer's disease: an update on genotype-phenotype relationships. J Alzheimers Dis 37(4): 653- 9 (2013).
47. Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, et al. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-epsilon4 carriers. PLoS Genet 9(8): e1003685 (2013).
48. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 119(5): 523-41 (2010).
49. Zheng L, Cedazo-Minguez A, Hallbeck M, Jerhammar F, Marcusson J, Terman A. Intracellular distribution of amyloid beta peptide and its relationship to the lysosomal system. Transl Neurodegener 1(1): 19 (2012).
50. Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang YW. Trafficking regulation of proteins in Alzheimer's disease. Mol Neurodegener 9: 6 (2014).
51. Nilsson P, Saido TC. Dual roles for autophagy: degradation and secretion of Alzheimer's disease Abeta peptide. Bioessays 36(6): 570-8 (2014).
52. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 60(4): 559-69 (2012).
53. Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, et al. Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener 9: 2 (2014).
54. Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med 16(12): 1370-1 (2010).
55. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des 14(16): 1601-5 (2008).
56. Zolezzi JM, Inestrosa NC. Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier. Mol Neurobiol 48(3): 438-51 (2013).
57. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075): 1503-6 (2012).
58. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 5(7): 1593-604 (2010).
59. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880): 535-9 (2002).
60. Deng Y, Xiong Z, Chen P, Wei J, Chen S, Yan Z. beta-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. Neurobiol Aging 35(3): 449-59 (2014).
61. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, et al. Activation of glycogen synthase kinase- 3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 45(1): 425-37 (2012).
62. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 33(2): 431, e27-38 (2012).
63. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-23 (2008).
64. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 239: 133-8 (2013).
65. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53(3): 292-304 (2003).
66. Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 8: 112 (2014).
67. Suzumura A. Neurotoxicity by microglia: the mechanisms and potential therapeutic strategy. Fukuoka Igaku Zasshi 100(7): 243-7 (2009).
68. Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol 1(4): 625-35 (2001).
69. Lee YJ, Choi DY, Choi IS, Kim KH, Kim YH, Kim HM, et al. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharideinduced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflam 9: 35 (2012).
70. Mizuno T. The biphasic role of microglia in Alzheimer's disease. Int J Alzheimers Dis 2012: 737846 (2012).
71. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 140(6): 918-34 (2010).
72. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184(1-2): 69-91 (2007).
73. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21(2): 372-81 (2001).
74. Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 30(11): 1885-9 (2009).
75. Leung R, Proitsi P, Simmons A, Lunnon K, Guntert A, Kronenberg D, et al. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One 8(6): e64971 (2013).
76. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47(2): 425-32 (1996).
77. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48(3): 626-32 (1997).
78. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci 2: Pii (2010).
79. Gupta S, Knight AG, Keller JN, Bruce-Keller AJ. Saturated longchain fatty acids activate inflammatory signaling in astrocytes. J Neurochem 120(6): 1060-71 (2012).
80. Liu L, Chan C. IPAF inflammasome is involved in interleukin- 1beta production from astrocytes, induced by palmitate; implications for Alzheimer's Disease. Neurobiol Aging 35(2): 309- 21(2014).
81. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14(2): 45-53 (2008).
82. Davis RE, Williams M. Mitochondrial function and dysfunction: an update. J Pharmacol Exp Ther 342(3): 598-607 (2012).
83. Texido L, Martin-Satue M, Alberdi E, Solsona C, Matute C. Amyloid beta peptide oligomers directly activate NMDA receptors. Cell Calcium 49(3): 184-90 (2011).
84. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316(5825): 750-4 (2007).
85. Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 282(31): 22406-13 (2007).
86. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 119(1): 7-35 (2010).
87. Verkhratsky A, Nedergaard M, Hertz L. Why are Astrocytes Important? Neurochem Res 40(2): 389-401 (2014).
88. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer's disease. Neurotherapeutics 7(4): 399-412 (2010).
89. Verkhratsky A, Rodriguez JJ, Parpura V. Astroglia in neurological diseases. Future Neurol 8(2): 149-58 (2013).
90. Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodriguez JJ, et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 4(3): Pii (2012).
91. Xiao M, Hu G. Involvement of aquaporin 4 in astrocyte function and neuropsychiatric disorders. CNS Neurosci Ther 20(5): 385-90 (2014).
92. Butt AM, Kalsi A. Inwardly rectifying potassium channels (Kir) in central nervous system glia: a special role for Kir4.1 in glial functions. J Cell Mol Med 10(1): 33-44 (2006).
93. Bano D, Nicotera P. Ca2+ signals and neuronal death in brain ischemia. Stroke 38(2): 674-6 (2007).
94. Piccini A, Borghi R, Guglielmotto M, Tamagno E, Cirmena G, Garuti A, et al. beta-amyloid 1-42 induces physiological transcriptional regulation of BACE1. J Neurochem 122(5): 1023-31 (2012).
95. Grolla AA, Fakhfouri G, Balzaretti G, Marcello E, Gardoni F, Canonico PL, et al. Abeta leads to Ca(2)(+) signaling alterations and transcriptional changes in glial cells. Neurobiol Aging 34(2): 511-22 (2013).
96. Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13(2): 54- 63 (2007).
97. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32(8): 421-31 (2009).
98. Agulhon C, Petravicz J, McMullen AB, Sweger EJ, Minton SK, Taves SR, et al. What is the role of astrocyte calcium in neurophysiology? Neuron 59(6): 932-46 (2008).
99. Kato S, Gondo T, Hoshii Y, Takahashi M, Yamada M, Ishihara T. Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 48(5): 332-40 (1998).
100. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 50(4): 427-34 (2005).
101. Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117(8): 919-47 (2010).
102. Halassa MM, Haydon PG. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol 72: 335-55 (2010).
103. Reichenbach A, Derouiche A, Kirchhoff F. Morphology and dynamics of perisynaptic glia. Brain Res Rev 63(1-2): 11-25 (2010).
104. Allen NJ, Barres BA. Neuroscience: Glia - more than just brain glue. Nature 457(7230): 675-7 (2009).
105. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60(3): 430-40 (2008).
106. Duran J, Saez I, Gruart A, Guinovart JJ, Delgado-Garcia JM. Impairment in long-term memory formation and learningdependent synaptic plasticity in mice lacking glycogen synthase in the brain. J Cereb Blood Flow Metab 33(4): 550-6 (2013).
107. Gibbs ME, Hutchinson D, Hertz L. Astrocytic involvement in learning and memory consolidation. Neurosci Biobehav Rev 32(5): 927-44 (2008).
108. Rodriguez JJ, Verkhratsky A. Neuroglial roots of neurodegenerative diseases? Mol Neurobiol 43(2): 87-96 (2011).
109. Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J Anat 221(3): 252-62 (2012).
110. Yeh CY, Vadhwana B, Verkhratsky A, Rodriguez JJ. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro 3(5): 271-9 (2011).
111. Koehler RC, Roman RJ, Harder DR. Astrocytes and the regulation of cerebral blood flow. Trends Neurosci 32(3): 160-9 (2009).
112. Petzold GC, Murthy VN. Role of astrocytes in neurovascular coupling. Neuron 71(5): 782-97 (2011).
113. Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58(9): 1094-103 (2010).
114. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4(147): 147ra11 (2012).
115. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, et al. Brainwide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest 123(3): 1299-309 (2013).
116. Nedergaard M. Neuroscience. Garbage truck of the brain. Science 340(6140): 1529-30 (2013).
117. Iliff JJ, Nedergaard M. Is there a cerebral lymphatic system? Stroke 44(6 Suppl 1): S93-5 (2013).
118. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science 342(6156): 373-7 (2013).
119. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348(13): 1215-22 (2003).
120. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12): 723-38 (2011).
121. Park KW, Yoon HJ, Kang DY, Kim BC, Kim S, Kim JW. Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer's disease. Psychiatry Res 203(2-3): 201-6 (2012).
122. Tang Z, Pi X, Chen F, Shi L, Gong H, Fu H, et al. Fifty percent reduced-dose cerebral CT perfusion imaging of Alzheimer's disease: regional blood flow abnormalities. Am J Alzheimers Dis Other Demen 27(4): 267-74 (2012).
123. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109(5-6): 813-36 (2002).
124. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 118(1): 87-102 (2009).
125. Bolanos JP, Almeida A, Moncada S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 35(3): 145-9 (2010).
126. Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med 32(4- 6): 247-57 (2011).
127. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11(10): 1193-206 (2010).
128. Fu W, Jhamandas JH. Role of astrocytic glycolytic metabolism in Alzheimer's disease pathogenesis. Biogerontology 15(6): 579-86 (2014).
129. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer's disease is associated with reduced expression of energy in posterior cingulate metabolism genes neurons. Proc Natl Acad Sci USA 105(11): 4441-46 (2008).
130. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci USA 107(41): 17763-7 (2010).
131. Hou L, Liu Y, Wang X, Ma H, He J, Zhang Y, et al. The effects of amyloid-beta42 oligomer on the proliferation and activation of astrocytes in vitro. In vitro Cell Dev Biol Anim 47(8): 573-80 (2011).
132. Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53(1): 37-46 (2012).
133. Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J 27(1): 187-98 (2013).
134. Pekny M, Wilhelmsson U, Pekna M. The dual role of astrocyte activation and reactive gliosis. Neurosci Lett 565: 30-8 (2014).
135. Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol 179(3): 1373-84 (2011).
136. Rossner S, Lange-Dohna C, Zeitschel U, Perez-Polo JR. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem 92(2): 226-34 (2005).
137. Zhao J, O'Connor T, Vassar R. The contribution of activated astrocytes to Abeta production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation 8: 150 (2011).
138. Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R. Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 58(10): 1235-46 (2010).
139. Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol 236(1): 1-5 (2012).
140. Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Abeta Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci 5: 98 (2013).
141. Dorfman VB, Pasquini L, Riudavets M, Lopez-Costa JJ, Villegas A, Troncoso JC, et al. Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiol Aging 31(10): 1743-57 (2010).
142. Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 26(43): 10939-48 (2006).
143. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Abeta clearance by transplanted adult astrocytes. Glia 59(11): 1643-57 (2011).
144. Mulder SD, Veerhuis R, Blankenstein MA, Nielsen HM. The effect of amyloid associated proteins on the expression of genes involved in amyloid-beta clearance by adult human astrocytes. Exp Neurol 233(1): 373-9 (2012).
145. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82(4): 239-59 (1991).
146. Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J, Vecsei L. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. J Alzheimers Dis 42 (3): S177-87 (2014).
147. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27(10): 1372-84 (2006).
148. Dringen R, Gutterer JM, Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 267(16): 4912-6 (2000).
149. White RE, Rao M, Gensel JC, McTigue DM, Kaspar BK, Jakeman LB. Transforming growth factor alpha transforms astrocytes to a growth-supportive phenotype after spinal cord injury. J Neurosci 31(42): 15173-87 (2011).
150. Hyder F, Fulbright RK, Shulman RG, Rothman DL. Glutamatergic function in the resting awake human brain is supported by uniformly high oxidative energy. J Cereb Blood Flow Metab 33(3): 339-47 (2013).
151. Schousboe A, Bak LK, Waagepetersen HS. Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA. Front Endocrinol (Lausanne) 4: 102 (2013).
152. Bak LK, Zieminska E, Waagepetersen HS, Schousboe A, Albrecht J. Metabolism of [U-13C]glutamine and [U-13C]glutamate in isolated rat brain mitochondria suggests functional phosphateactivated glutaminase activity in matrix. Neurochem Res 33(2): 273-8 (2008).
153. Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed 24(8): 943-57 (2011).
154. Cruz NF, Ball KK, Dienel GA. Functional imaging of focal brain activation in conscious rats: impact of [(14)C]glucose metabolite spreading and release. J Neurosci Res 85(15): 3254-66 (2007).
155. Karki P, Smith K, Johnson J, Jr., Aschner M, Lee E. Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: Putative mechanism for manganese-induced neurotoxicity. Neurochem Int 13: pii: S0197- 0186(14)00185-5 (2014).
156. Kirvell SL, Esiri M, Francis PT. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 98(3): 939-50 (2006).
157. Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet- Bianco C, et al. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 29(11): 1619-30 (2008).
158. Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol Aging 34(10): 2341-51 (2013).
159. Canas PM, Simoes AP, Rodrigues RJ, Cunha RA. Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer's disease. Neuropharmacology 76: 51-56 (2014).
160. Sokolow S, Luu SH, Nandy K, Miller CA, Vinters HV, Poon WW, et al. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Neurobiol Dis 45(1): 381-7 (2012).
161. Zou J, Wang YX, Dou FF, Lu HZ, Ma ZW, Lu PH, et al. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem Int 56(4): 577-84 (2010).
162. Schallier A, Smolders I, Van Dam D, Loyens E, De Deyn PP, Michotte A, et al. Region- and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer's disease. J Alzheimers Dis 24(2): 287-300 (2011).
163. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci 33(12): 5312-8 (2013).
164. Matos M, Augusto E, Oliveira CR, Agostinho P. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156(4): 898-910 (2008).
165. Mota SI, Ferreira IL, Rego AC. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors. Neuropharmacology 76 Pt A: 16-26 (2014).
166. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev 12(3): 757-63 (2013).
167. Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience 158(4): 1446-59 (2009).
168. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5(5): 405-14 (2002).
169. Kessels HW, Nabavi S, Malinow R. Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci USA 110(10): 4033-8 (2013).
170. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27(11): 2846-57 (2007).
171. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68(6): 1067-81 (2010).
172. Escobar ML, Derrick B. Long-Term Potentiation and Depression as Putative Mechanisms for Memory Formation (2007).
173. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31(18): 6627-38 (2011).
174. Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13(7): 812-8 (2010).
175. Vamos E, Fejes A, Koch J, Tajti J, Fulop F, Toldi J, et al. Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. Headache 50(5): 834-43 (2010).
176. Vamos E, Pardutz A, Varga H, Bohar Z, Tajti J, Fulop F, et al. lkynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 57(4): 425-9 (2009).
177. Chauvel V, Vamos E, Pardutz A, Vecsei L, Schoenen J, Multon S. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol 236(2): 207-14 (2012).
178. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 26(8): 2211-21 (2007).
179. Maciejak P, Szyndler J, Turzynska D, Sobolewska A, Plaznik A. Kynurenic acid: a new effector of valproate action? Pharmacol Rep 63(6): 1569-73 (2011).
180. Zadori D, Nyiri G, Szonyi A, Szatmari I, Fulop F, Toldi J, et al. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm 118(6): 865-75(2011).
181. Zadori D, Klivenyi P, Toldi J, Fulop F, Vecsei L. Kynurenines in Parkinson's disease: therapeutic perspectives. J Neural Transm 119(2): 275-83 (2012).
182. Tan L, Yu JT. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 323(1-2): 1-8 (2012).
183. Vecsei L, Ed. Kynurenines in the Brain: From Experiments to Clinics. New York: Nova Science Publishers Inc (2005).
184. Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 136: 1-186 (1974).
185. Gal EM, Sherman AD. Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem 30(3): 607-13 (1978).
186. Yu P, Li Z, Zhang L, Tagle DA, Cai T. Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene 365: 111-8 (2006).
187. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12(1): 64-82 (2013).
188. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52(4): 1319-2 (1989).
189. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247(1): 184-7 (1982).
190. Yang GY, Woo YW, Park MK, Bae YC, Ahn DK, Bonfa E. Intracisternal administration of NR2 antagonists attenuates facial formalin-induced nociceptive behavior in rats. J Orofac Pain 24(2): 203-11 (2010).
191. Park MK, Lee JH, Yang GY, Won KA, Kim MJ, Park YY, et al. Peripheral administration of NR2 antagonists attenuates orofacial formalin-induced nociceptive behavior in rats. Prog Neuropsychopharmacol Biol Psychiatry 35(4): 982-6 (2011).
192. Martins MA, De Castro Bastos L, Melo NE, Tonussi CR. Dependency of nociception facilitation or inhibition after periaqueductal gray matter stimulation on the context. Behav Brain Res 214(2): 260-7 (2010).
193. Ohshiro H, Tonai-Kachi H, Ichikawa K. GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 365(2): 344-8 (2008).
194. Cosi C, Mannaioni G, Cozzi A, Carla V, Sili M, Cavone L, et al. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 60(7-8): 1227- 31 (2011).
195. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281(31): 22021-8 (2006).
196. Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm 119(2): 133-9 (2012).
197. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34(2): 136-43 (2013).
198. Pineda-Farias JB, Perez-Severiano F, Gonzalez-Esquivel DF, Barragan-Iglesias P, Bravo-Hernandez M, Cervantes-Duran C, et al. The L-kynurenine-probenecid combination reduces neuropathic pain in rats. Eur J Pain 17(9): 1365-73 (2013).
199. Horvath G, Kekesi G, Tuboly G, Benedek G. Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level. Brain Res 1155: 42-8 (2007).
200. Zador F, Kocsis D, Borsodi A, Benyhe S. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. Neurochem Int 67: 14-22 (2014).
201. Lapin P. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. Journal of Neural Transmission 42(1): 37-43 (1978).
202. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55(4): 1327-39 (1990).
203. Jauch D, Urbanska EM, Guidetti P, Bird ED, Vonsattel JP, Whetsell WO, Jr., et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci 130(1): 39-47 (1995).
204. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17(3): 455-61 (2004).
205. Csillik A, Knyihar E, Okuno E, Krisztin-Peva B, Csillik B, Vecsei L. Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain. Exp Neurol 177(1): 233-41 (2002).
206. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets 9(6): 791-800 (2010).
207. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol 197(1): 31-40 (2006).
208. Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol 124(2): 391-9 (1998).
209. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl (70): 285-304 (2006).
210. Zadori D, Klivenyi P, Vamos E, Fulop F, Toldi J, Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 116(11): 1403-9 (2009).
211. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42(9): 1702-6 (1992).
212. Knyihar-Csillik E, Csillik B, Pakaski M, Krisztin-Peva B, Dobo E, Okuno E, et al. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience 126(4): 899-914 (2004).
213. Knyihar-Csillik E, Chadaide Z, Mihaly A, Krisztin-Peva B, Fenyo R, Vecsei L. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathologica 112(2): 127-37 (2006).
214. Luchowski P, Luchowska E, Turski WA, Urbanska EM. 1-Methyl- 4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci Lett 330(1): 49-52 (2002).
215. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci 239(1): 31-5 (2005).
216. Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L. 3- hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord 28(12): 1653-60 (2013).
217. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 107(3): 343-53 (2000).
218. Yamada A, Akimoto H, Kagawa S, Guillemin GJ, Takikawa O. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J Neurochem 110(3): 791-800 (2009).
219. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106(2): 165-81 (1999).
220. Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur Arch Psychiatry Clin Neurosci 263(4): 345-52 (2013).
221. Wu W, Nicolazzo JA, Wen L, Chung R, Stankovic R, Bao SS, et al. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One 8(4): e59749 (2013).
222. Mourdian MM, Heyes MP, Pan JB, Heuser IJ, Markey SP, Chase TN, et al. No changes in central quinolinic acid levels in Alzheimer's disease. Neurosci Lett 105(1-2): 233-8 (1989).
223. Hartai Z, Juhasz A, Rimanoczy A, Janaky T, Donko T, Dux L, et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 50(2): 308-13 (2007).
224. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115 (Pt 5): 1249-73 (1992).
225. Wennstrom M, Nielsen HM, Orhan F, Londos E, Minthon L, Erhardt S. Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies. Int J Tryptophan Res 7: 1-7 (2014).
226. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566(1-3): 261-9 (2004).
227. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313(1-2): 96-8 (2001).
228. Rozsa E, Robotka H, Vecsei L, Toldi J. The Janus-face kynurenic acid. J Neural Transm 115(8): 1087-91 (2008).
229. Prescott C, Weeks AM, Staley KJ, Partin KM. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 402(1-2): 108-12 (2006).
230. Zadori D, Klivenyi P, Plangar I, Toldi J, Vecsei L. Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15(4): 701-17 (2011).
231. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Bloodbrain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56(6): 2007-17 (1991).
232. Bahn A, Ljubojevic M, Lorenz H, Schultz C, Ghebremedhin E, Ugele B, et al. Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol 289(5): C1075-84 (2005).
233. Nagy K, Plangar I, Tuka B, Gellert L, Varga D, Demeter I, et al. Synthesis and biological effects of some kynurenic acid analogs. Bioorg Med Chem 19(24): 7590-6 (2011).
234. Marosi M, Nagy D, Farkas T, Kis Z, Rozsa E, Robotka H, et al. A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J Neural Transm 117(2): 183-8 (2010).
235. Drieu K. Preparation and definition of Ginkgo biloba extract. Presse Med 15(31): 1455-7 (1986).
236. Turski MP, Turska M, Zgrajka W, Kuc D, Turski WA. Presence of kynurenic acid in food and honeybee products. Amino Acids 36(1): 75-80 (2009).
237. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154(1): 85-7 (1988).
238. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21(19): 7463-73 (2001).
239. Fukuyama K, Tanahashi S, Hoshikawa M, Shinagawa R, Okada M. Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway. Neuropharmacology 76 Pt A: 137-45 (2014).